Holen Sie sich die Stockscreener-App
47.92
2.08%
-0.9492
Schlusskurs vom Vortag:
$48.87
Offen:
$49.7
24-Stunden-Volumen:
1.04M
Relative Volume:
0.56
Marktkapitalisierung:
$4.61B
Einnahmen:
$3.51M
Nettoeinkommen (Verlust:
$-581.60M
KGV:
-7.356
EPS:
-6.5145
Netto-Cashflow:
$-345.93M
1W Leistung:
-15.30%
1M Leistung:
-9.83%
6M Leistung:
-14.94%
1J Leistung:
+13.97%
1-Tages-Spanne:
$47.53
$50.07
1-Wochen-Bereich:
$47.53
$59.06
52-Wochen-Spanne:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
47.99 | 4.69B | 3.51M | -581.60M | -345.93M | -6.5145 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.37 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.22 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.32 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.61 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.49 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Q2 EPS Estimate for CRISPR Therapeutics Lifted by Analyst - MarketBeat
Cathie Wood’s ARK Invest Buys $10M in CRISPR and PayPay on Thursday - CoinCentral
ARK Investment Acquires 113K Shares of Crispr Therapeutics (CRSP) - GuruFocus
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells 2,800 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 9,798 Shares - MarketBeat
CRISPR Therapeutics (CRSP) CEO RSU vesting and 9,798-share tax sale - Stock Titan
Assessing CRISPR Therapeutics (CRSP) Valuation After Upsized US$550m Convertible Notes Offering - simplywall.st
CRISPR Therapeutics plans $350M convertible notes offering By Investing.com - Investing.com Nigeria
Research Analysts Set Expectations for CRSP FY2028 Earnings - MarketBeat
CRISPR Therapeutics prices $550M convertible notes offering By Investing.com - Investing.com Canada
CRISPR Therapeutics AG (CRSP) Falls Sharper Than Overall Market: Key Information to Note - Bitget
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance
CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth - Insider Monkey
CRISPR Therapeutics Announces $350 Million Convertible Senior Notes Offering to Fund Gene-Editing Innovation - Minichart
CRISPR Therapeutics (CRSP) Sees Significant ARK Invest Purchase - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Sees Strong Trading VolumeHere's What Happened - MarketBeat
CRISPR Therapeutics prices $550 million convertible senior notes offering - The Pharma Letter
CRISPR Therapeutics (CRSP) Stock Plunges 10% as Cathie Wood’s ARK Invest Scoops Up Shares - MEXC
CRISPR Therapeutics (CRSP) Reports Wider Q4 Loss of $1.37/Share on Zero Revenue; Shares Plunge 10% - AlphaStreet
CRISPR Therapeutics (CRSP) Stock Drops 10% — Cathie Wood’s Ark Buys the Dip - MEXC
CRISPR Therapeutics (CRSP) Upsizes Convertible Note Offering to $550M - GuruFocus
CRISPR Therapeutics (CRSP) Announces $550M Convertible Notes Offering - GuruFocus
Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million - TipRanks
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering - The Manila Times
CRISPR Therapeutics prices $550M upsized convertible notes due 2031 - TradingView
CRISPR Therapeutics AG Prices $550 Million Convertible Senior Notes Offering Due 2031 - Quiver Quantitative
CRISPR Therapeutics prices $550M convertible notes offering - Investing.com
Investors back CRISPR $550M notes, 45% premium conversion price - Stock Titan
CRISPR Therapeutics (CRSP) Stock Plunges 10% as Cathie Wood's ARK Invest Scoops Up Shares - Blockonomi
Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics (CRSP:NASDAQ) - Seeking Alpha
Capital International Investors Acquires 55,511 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (CRSP) Announces $350M Convertible Notes Off - GuruFocus
This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday - The Motley Fool
This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday - The Motley Fool
CRSP Stock Declines Over 9% as Market Faces Downturn - GuruFocus
What's Going On With CRISPR Therapeutics Stock Today? - Benzinga
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap DownWhat's Next? - MarketBeat
Crispr Therapeutics Falls on $350 Million Senior Note Private Placement - marketscreener.com
Here is Why CRISPR Therapeutics (CRSP) Appears so Good - Bitget
CRISPR Therapeutics plans $350M convertible notes offering - Investing.com India
CRISPR Therapeutics stock dips on $350M convertible debt offering - MSN
Crispr Therapeutics Plans $350 Million Convertible Senior Notes Offering - marketscreener.com
Crispr Therapeutics announces proposed convertible senior notes offering - TipRanks
CRISPR Therapeutics stock falls on convertible notes offering - Investing.com India
Why Crispr Therapeutics Stock Is Sliding Today - TipRanks
CRISPR Therapeutics stock falls on convertible notes offering By Investing.com - Investing.com UK
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering - The Manila Times
CRISPR Therapeutics seeks $350M in 2031 convertible debt - Stock Titan
Why Is CRSP (CRISPR Therapeutics) Stock Falling Pre-Market Today? - Stocktwits
Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics Pivots Beyond Casgevy, Highlights CTX310 Data and New Cardiovascular Push - MarketBeat
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):